The 3 Most Common Rejection Reasons During an Interview

The 3 Most Common Rejection Reasons During an Interview

In this episode, I discuss the three most common reasons hiring managers reject candidates, focusing on aspects that are often within the candidate's control. I highlight the importance of cultural fit, alignment of interests, and clarity in communication during interviews. I give tips to improve your interview performance and avoid common pitfalls that lead to rejection.

Here's what you're in:

  • How cultural fit can be influenced by candidate behavior?
  • How using vague terms like 'strategy' can lead to misunderstandings?
  • Why building rapport with interviewers is crucial for success?

Timestamps:

01:09 Background Story

03:37 Not a Good Cultural Fit

07:29 Candidates Going To Get Bored/ Not Hands-on Enough

12:01 Not Giving Straight to the Point Answers

16:52 Summary


About Me

My name is Charles Spence and I lead Discera. After many years working in the life-science recruitment world, I decided to work for myself. Before doing recruitment I graduated with a biomedical degree, have worked in hospitals (including translation work in Seoul, South Korea), and also spent a year working in diabetes research in Stockholm. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, I decided to launch my firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.


Connect with me:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(74)

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

Eliot Forster, CEO at Levicept on 30 Years in Pharma, Running a Six-Person Biotech, and the Future of European Drug Development

In this episode, I talked with Eliot Forster, CEO of Levicept, a neurophysiologist-turned biotech veteran with 30+ years of experience across Big Pharma and a series of CEO roles. We get into clinical...

7 Sep 45min

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

Michael Zaiac, Medical Affairs Lead for Oncology at Daiichi Sankyo on 30 Years of Hiring Lessons, The ADC Wave, and Building Teams in a Fast-Moving Pipeline

In this episode, I talked with Michael Zaiac, Medical Affairs Lead for Oncology across Europe and Canada at Daiichi Sankyo — a trained surgical oncologist who walked away from the operating table, mov...

24 Aug 39min

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

Juho Jalkanen, CEO at Faron Pharmaceuticals on From Surgeon to CEO, Rethinking Boards, and Fighting for the Right Science

In this episode, I talked with Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals — a publicly listed Finnish biotech building novel immunotherapies for blood cancers. Juho's path is unlike most you'll h...

10 Aug 37min

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

Tobias Kampfenkel, MD, MHBA, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine, on Transformative Drugs in Oncology and Autoimmunity: It's Always the Team!

In this episode, I talked with Dr. Tobias Kampfenkel, Vice President of Early Clinical Development and Translational Research at Miltenyi Biomedicine. Tobias spent nearly a decade at Janssen building ...

15 Juni 39min

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

Sofia Heigis, CEO of OncoPeptides, From Sales Rep to CEO, Being "Present", and Hiring for Self-Insight

In this episode, I talked with Sofia Heigis, Chief Executive Officer of OncoPeptides, about a career path that did not start where she expected. Sofia originally wanted to move into clinical operation...

31 Maj 38min

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

Jens Lindberg, CEO at Medivir, on The Biotech Rollercoaster - Medivir´s Previous Four Months (and Biotech Today in 2026)

In this episode, I talked with Jens Lindberg, CEO of Medivir AB, a Swedish biotech developing innovative therapies in liver cancer and rare disease. Jens brings over 30 years of late-stage development...

18 Maj 33min

Hubert Truebel,  Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

Hubert Truebel, Managing Director at DEBRA Research, on Creating Own Career Opportunities...and a Practical Approach to Longevity

In this episode, I talked with Hubert Truebel, Managing Director at DEBRA Research, to discover a career that wasn’t built traditionally—but through creating opportunities where none formally existed....

4 Maj 28min

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

Sampreet Ramachandra, Head of Hematology Business Unit at Novartis Germany, on Launching Without a Playbook, Hiring Mistakes, and Leading with Equity

In this episode, I talked with Sampreet Ramachandra, Head of the Hematology Business Unit at Novartis Germany, about what it really takes to lead high-stakes launches — and what leadership looks like ...

30 Mars 42min

Populärt inom Business & ekonomi

framgangspodden
varvet
rss-jossan-nina
rss-borsens-finest
24fragor
svd-tech-brief
avanzapodden
badfluence
uppgang-och-fall
lastbilspodden
fill-or-kill
rss-inga-dumma-fragor-om-pengar
rss-kort-lang-analyspodden-fran-di
tabberaset
rss-dagen-med-di
bathina-en-podcast
rikatillsammans-om-privatekonomi-rikedom-i-livet
kapitalet-en-podd-om-ekonomi
affarsvarlden
borsmorgon